Fovero Therapeutics
June 16, 2025
Company Presentation
Oncology
154
Fovero Therapeutics is a pre-clinical biotech developing novel immunotherapies for cancer and autoimmune diseases. Our lead program, FT002, is a best-in-class antibody targeting Galectin-9, with a mechanistically distinct MoA from other GAL-9 antibodies. It reprograms anti-tumor immunity in MSS colorectal cancer and triple-negative breast cancer, delivering complete tumor clearance and durable protection in preclinical models.
Our second asset, FT024, is a first-in-class therapy for autoimmune and inflammatory diseases, acting on an unaddressed immune pathway to restore immune balance.
Supported by US$2M in non-dilutive funding (Brandon BioCatalyst, U.S. DoD), both assets are advancing toward IND-enabling studies. Fovero is seeking strategic partners and investors to co-develop or license these differentiated therapies as they move into clinical development.
Company HQ City:
Brisbane
Company HQ State:
Queensland
Company HQ Country:
Australia
Year Founded:
2023
Lead Product in Development:
FT002 for oncology
CEO
Robert McLachlan
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
Two
When you expect your next catalyst update?
Initiation of IND-enabling studies for FT002, supported by strong preclinical efficacy and translational data. This milestone will mark our transition from discovery to development, positioning FT002 for regulatory submission and first-in-human trials in MSS colorectal and triple-negative breast cancers. We also expect to share new biomarker and mechanistic insights that support FT002’s differentiation.
A second catalyst will follow with preclinical proof-of-concept for FT024, our first-in-cl
What is your next catalyst (value inflection) update?
September 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}